Biased agonism of the angiotensin II receptor is known to promote cardiac contractility. Our laboratory indicated that these effects may be attributable to changes at the level of the myofilaments. However, these signaling mechanisms remain unknown. Because a common finding in dilated cardiomyopathy is a reduction in the myofilament-Ca 2+ response, we hypothesized that β-arrestin signaling would increase myofilament-Ca 2+ responsiveness in a model of familial dilated cardiomyopathy and improve cardiac function and morphology.
I
n results described here, we present novel evidence on a potential therapeutic approach in familial dilated cardiomyopathy (DCM) of ligands acting at the angiotensin II receptor (AT1R) with a bias toward promotion of β-arrestin 2 signaling. There is substantial evidence that drugs that have the net effect of reducing angiotensin II (ang II) stimulation of the AT1R, either by inhibiting the production of active octapeptide through angiotensinconverting enzyme inhibitors, or antagonizing the receptor via AT1R blockers (ARBs), have therapeutic benefit in cardiovascular disease. Therefore, these drugs are indicated as the first line in the treatment of many cardiovascular diseases. 1 It is now clear that induction of maladaptive ang II signaling via the AT1R also induces adaptive signaling mediated through β-arrestin. 2, 3 Our evolving understanding of the complexity of the various ligandbound and unbound conformations of the AT1R has led to the development of biased ligands. 4 β-Arrestin-biased ligands targeted to the AT1R act as angiotensin receptor modulators, having properties similar to ARBs in that they selectively block ang II binding to the AT1R and subsequent G-protein coupling, while simultaneously and selectively activating β-arrestin signaling pathways. 5, 6 In view of evidence that a consequence of biased ligand interactions with the AT1R is a promotion of cardiac myocyte contractility with no change in the Ca 2+ transient, we set out to test whether downstream β-arrestin signaling involves a modification of the myofilament-Ca 2+ response. 7, 8 Previously, we found that biased agonism of the AT1R in the face of chronic ang II infusion in rats was able to preserve the myofilament-Ca 2+ response and prevent ang II-mediated maladaptation. 9 Because a decrease in myofilament-Ca 2+ response is a common molecular pathology found in DCM, we hypothesized that modulating the response from the AT1R by using biased ligands may be a viable therapeutic approach to the treatment of DCM. 10, 11 In the first line of experiments, we tested the effect of acute infusion of a β-arrestin-biased ligand on in situ cardiac contractility in a mouse model of familial DCM. Our data revealed that, unlike treatment with a conventional ARB, a 15-minute infusion of a biased ligand in the familial DCM model restored contractility to normal levels as determined from left ventricular pressure-volume relations. 12 The mechanism of this effect requires further study. Moreover, the results of the acute study suggested that β-arrestin-biased agonism of AT1R would provide benefit in chronic progression of DCM.
To test this hypothesis, we used a mouse model of DCM expressing a cardiac-directed missense mutation in the sarcomeric protein, α-tropomyosin (Tm), where a glutamic acid has been exchanged for a lysine at residue 54 (Tm-E54K). 13 This mutation causes a disruption in the coiled-coil structure of Tm in an actin-binding region resulting in a constitutive decrease in the myofilament-Ca 2+ response and a DCM-like phenotype consistent with the human presentation of the disease. 14 We treated nontransgenic (NTG) littermates and Tm-E54K mice for 3 months beginning at 1 month of age, when DCM phenotypic changes were already evident, with a β-arrestin-biased ligand, TRV120067 (TRV067), or an ARB, losartan.
METHODS
Expanded materials and methods can be found in the onlineonly Data Supplement.
Study Objective and Design
The objective of this study was to examine the effect of chronic AT1R-biased ligand treatment on the structure and function of a mouse model of familial DCM. NTG and Tm-E54K mice were randomly assigned to 3 experimental groups: (1) untreated, (2) TRV067 treated, or (3) losartan treated. Echocardiography was used to assess cardiac function and morphology; in vivo, histology was used to assess cardiac structure; detergentextracted fiber bundles were used to assess the myofilament-Ca 2+ response; and Western blots were used to assess signaling pathways altered because of treatment. Neonatal rat ventricular myocytes were used in culture to confirm signaling pathways and determine protein localization using Western blotting and immunocytochemistry.
Animal Model and Institutional Approval
All experiments involving the use of animals were given prior approval by the IACUC at the University of Illinois at Chicago, AAALAC accredited. Mice were maintained in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (National Institutes of Health, Eighth Edition, revised 2011). Male and female mice heterozygous for the Tm-E54K mutation, or
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What Is New?
• Chronic treatment of a dilated cardiomyopathy mouse model with a biased ligand acting at the angiotensin II receptor induces activation of novel signaling pathways via β-arrestin that compensates for depressed cardiac function.
• A previously unrecognized interaction of β-arrestin with the sarcomere may be involved in modulating the myofilament-Ca 2+ response through alterations in MLC2v phosphorylation.
What Are the Clinical Implications?
• Modulation of the myofilament-Ca 2+ response, targeted directly or by altering signaling pathways, may be of therapeutic benefit in a variety of cardiomyopathies.
• Novel β-arrestin signaling pathways that improve cardiac function and structure in dilated cardiomyopathy could be targeted for therapeutic intervention.
NTG littermates, were treated for 3 months beginning at 1 month of age. Controls were untreated littermates. All mice were euthanized by cardiectomy under surgical anesthesia using a ketamine/xylazine (200 mg/kg, 20 mg/kg) mixture, in accordance with the American Veterinary Medical Association Panel on Euthanasia Guidelines (American Veterinary Medical Association, 2013 edition).
Statistical Analyses
Two hypotheses were tested for chronic animal studies. The first hypothesis addressed if there was a significant change because of the genotype. The second hypothesis tested was if drug treatment significantly altered a parameter within the genotype. To test for a Gaussian distribution, normality was assessed using the Kolmogorov-Smirnov test with DallalWilkinson-Lilliefors P value. The Brown-Forsythe test was used to determine equal variance of the standard deviation. As indicated in figure legends, an unpaired 2-tailed Student t test was used for comparison of 2 independent variables, a 1-way analysis of variance was used for comparisons of 1 independent variable to compare ≥3 groups followed by the Tukey post hoc test for multiple comparisons, a 2-way analysis of variance was performed where 2 independent variables were considered, followed by the Tukey post hoc test for multiple comparisons, or a repeated-measures 2-way analysis of variance was performed followed by the Bonferroni post hoc test for multiple comparisons. All data are presented as means±standard error of the mean and significance set at P<0.05. All statistical analysis was performed using GraphPad Prism 6.0 Software (GraphPad, Inc). Table I ). 14 The transgenic protein comprised ≈23% of the Tm expressed in the Tm-E54K mice, not leading to an overall increase in Tm expression (online-only Data Supplement Figure IIA and IIB). We noted no significant sex-related functional or structural differences within the genotype (online-only Data Supplement Table II ). After treatment with TRV067, Tm-E54K mice had a significant improvement in systolic function in comparison with both Tm-E54K untreated and losartan-treated mice. Associated with TRV067 treatment in Tm-E54K mice, there were significant increases in ejection fraction, fractional shortening, velocity of circumferential fiber shortening, stroke volume, and cardiac output, without an increase in heart rate. There were also increases in left ventricular anterior wall dimension at systole and increases in left ventricular posterior wall dimension at systole (online-only Data Supplement Figure IIIA and IIIB). Although TRV067 significantly improved cardiac performance and morphology, it was not able to reverse these measures to those of NTG animals. There were no changes in cardiac function in Tm-E54K mice treated with losartan in comparison with Tm-E54K untreated mice. We found no effect on cardiac function of any treatment in NTG mice.
RESULTS

TRV067 Is a β-Arrestin 2-Biased Ligand
Histological analysis revealed there was a decrease in cell cross-sectional area in hearts of Tm-E54K untreated mice in comparison with NTG untreated controls. TRV067 significantly increased cross-sectional cell area, whereas losartan had no effect. Although TRV067 had no effect in NTG mice, losartan induced a significant decrease in cross-sectional cell area (online-only Data Supplement Figure IV ).
β-Arrestin Signaling Increases Cardiac Myofilament-Ca 2+ Responsiveness
We sought to understand if biophysical changes at the level of the sarcomere could be responsible for the improvements in cardiac function seen in echocardiography. Detergent-extracted fiber bundles isolated from Tm-E54K mice had a significantly reduced myofilament-Ca 2+ sensitivity, as measured by the Ca 2+ concentration at halfmaximal tension (pCa 50 ) and maximum tension generation (Table) . TRV067 treatment improved maximum tension generation to that of untreated NTG animals and significantly improved pCa 50 in Tm-E54K fibers. Losartan had no significant effect on myofilament maximum tension generation or pCa 50 in Tm-E54K mice (Table 1, Figure 1A and 1B). There was no effect on pCa 50 , maximum tension generation, or Hill coefficient (n H ) in fibers isolated from TRV067-treated NTG mice in comparison with untreated controls. It is interesting to note that fibers isolated from losartan-treated NTG mice showed a significant decrease in pCa 50 in comparison with both TRV067 and untreated NTG groups, and a decrease in maximum tension generation, as well (Table, Figure 1A and 1B).
β-Arrestin Signaling Alters Myofilament Protein Phosphorylation
To understand the mechanism(s) for the TRV067-induced increases in the myofilament-Ca 2+ response, we investigated posttranslational modifications of sarcomeric proteins. We found significant alterations in phosphorylation of cardiac troponin I (cTnI), troponin T, and MLC2v.
ProQ diamond phospho-protein stain revealed no significant changes in the total phosphorylation of cardiac myosin-binding protein-C (cMyBP-C), desmin, Tm, or cTnI. Losartan-treated Tm-E54K mice displayed a significant decrease in troponin T phosphorylation in comparison with TRV067-treated Tm-E54K mice and TRV067-treated mice displayed a significant increase in MLC2v phosphorylation ( Figure 2A ).
We used phospho-specific antibodies, where possible, to perform a more detailed analysis of myofilament protein phosphorylation. There were no changes in sitespecific phosphorylation of cMyBP-C or Tm. There was a significant increase in phosphorylation at S23/24 in both the TRV067-and losartan-treated Tm-E54K mice.
We used Phos-Tag gel electrophoresis to analyze phosphorylation of MLC2v. TRV067 increased MLC2v phosphorylation in Tm-E54K mouse hearts in comparison with myofilaments from both losartan-treated and untreated Tm-E54K mice. MLC2v phosphorylation was significantly decreased in losartan-treated NTG mice in comparison with NTG untreated mice ( Figure 2B ).
TRV067 Treatment Stimulated Signaling Pathways Associated With an Improvement in Cardiac Function
We performed an analysis of various signaling pathways to better understand which pathways may be activated by β-arrestin and what alterations in signaling may be at- Force-Ca 2+ relationship of fibers isolated from NTG untreated, TRV067-and losartan-treated animals (A) and Tm-E54K untreated, TRV067-and losartan-treated animals (B) following treatment for 3 months. Data were analyzed by 2-way ANOVA followed by Tukey post hoc test for multiple comparisons and represented as means±SEM. n = 3 to 4 hearts per group, 6 to 8 fibers per group. ANOVA indicates analysis of variance; DCM, dilated cardiomyopathy; NTG, nontransgenic; and SEM, standard error of the mean. A, Representative ProQ diamond and Coomassie R-250 stained gels and summarized analysis showing MLC2v phosphorylation was significantly increased in TRV067-treated Tm-E54Ks mice and decreased TnT phosphorylation in Tm-E54K losartan-treated mice. B, Representative Western blots and summarized quantification of phospho-specific antibodies to cMyBP-C, Tm, and cTnI showing a significant increase in p-cTnI S23/24 in TRV067-and losartan-treated Tm-E54K mice and MLC2v phosphorylation significantly increased in TRV067-treated Tm-E54Ks mice and decreased in NTG losartan-treated mice. Data were analyzed by 2-way ANOVA followed by a Tukey post hoc test for multiple comparisons and represented as means±SEM. n = 4 to 6 hearts per group. *P≤0.05. **P≤0.01. ANOVA indicates analysis of variance; cTnI, cardiac troponin I; NTG, nontransgenic; SEM, standard error of the mean; Tm, α-tropomyosin; and TnT, troponin T. tributable solely to inhibition of Gα q coupling in our model of familial DCM.
We found that both TRV067 and losartan were able to alter Akt-GSK signaling in Tm-E54K mice, indicating a common mechanism of action through the inhibition of Gα q coupling. In comparison with untreated NTG hearts, Akt phosphorylation at S473 and GSK-3β phosphorylation at S9 were both increased in untreated Tm-E54K hearts ( Figure 3A ). This suggests that the Tm-E54K mutation induces an increase in Akt activity and a concomitant decrease in GSK-3β activity ( Figure 3B ).
15 TRV067 and losartan both decreased Akt and GSK-3β phosphorylation in the Tm-E54K hearts ( Figure 3A and 3B). Evidence indicates that GSK-3β-related phosphorylation of β-catenin regulates its degradation. 16 Although we did not observe a decrease in β-catenin phosphorylation in untreated Tm-E54K mice in comparison with untreated NTG mice, we did observe an increase in β-catenin phosphorylation in both TRV067-and losartan-treated Tm-E54K mice ( Figure 3C ). There was no change in Akt, Figure 3 . The Akt-GSK-3β pathway is downregulated in chronic TRV067-and losartan-treated Tm-E54K mice.
Representative Western blots and summarized quantification showing Akt phosphorylation was decreased in TRV067-and losartan-treated Tm-E54K mice and GSK-3β phosphorylation was decreased (A). B, There was a concomitant increase in β-catenin phosphorylation in these mice. C, An increase in phosphorylation of phospholamban at S16 was also seen in both TRV067-and losartan-treated mice, but not at T17. Data were analyzed by 2-way ANOVA followed by a Tukey post hoc test for multiple comparisons and represented as means±SEM. n = 4 to 6 hearts per group. *P≤0.05. **P≤0.01. ***P≤0.001. ANOVA indicates analysis of variance; NTG, nontransgenic; and SEM, standard error of the mean. GSK-3β, or β-catenin phosphorylation in NTG hearts regardless of treatment ( Figure 3A through 3C) . We also found that Tm-E54K mice treated with TRV067 or losartan both showed an increase in phosphorylation of phospholamban (PLN) at the S16 site, but not the T17 site. Losartan-treated NTG mice also showed an increase in S16 phosphorylation of PLN in comparison with untreated controls ( Figure 3C) .
A common finding in mouse models of heart failure is an increase in the isoform content of β-myosin heavy chain (β-MHC), which may be attributable to the activation of G proteins. Our model has been previously shown to have an increase in β-MHC expression.
14 Because β-MHC expression may be regulated by downstream β-catenin target genes, we compared the protein expression levels of β-MHC in treated and untreated NTG and Tm-E54K hearts. 17, 18 NTG hearts demonstrated no expression of β-MHC. There was a significant reexpression of β-MHC to ≈30% of the isoform content in the untreated Tm-E54K hearts in comparison with NTG control hearts. This was reduced to ≈10% expression with both TRV067 and losartan treatment (online-only Data Supplement Figure V) . ERK1/2 phosphorylation is activated by β-arrestin 2-biased agonism of the AT1R and is used as a marker of β-arrestin activation. 19 We found that ERK1/2 phosphorylation was increased in TRV067-treated Tm-E54K and NTG hearts, but not in hearts of losartan-treated mice ( Figure 4A ). We hypothesized that downstream signaling from ERK1/2 may also be activated in our mice, and this signaling may be an upstream signaling mediator responsible for the changes in posttranslational modifications of MLC2v. We examined RSK3, a serine-threonine kinase, a known downstream target of ERK1/2, which has been implicated in the phosphorylation of MYPT1 in vascular smooth muscle cells, and serum response factor (SRF) phosphorylation, as well, which is involved in the transcription of cardiac-specific genes in the heart, such as SERCA. [20] [21] [22] TRV067 increased RSK3, SRF, and MYPT1/2 phosphorylation in both NTG and Tm-E54K mice. Losartan had no effect on RSK3, SRF, or MYPT1/2 phosphorylation. This difference in response between TRV067 and losartan suggests a mechanism reliant on β-arrestin ( Figure 4A ). At baseline, RSK3 phosphorylation was significantly decreased in untreated Tm-E54K mice in comparison with untreated NTG mice ( Figure 4A ). We found a significant decrease in SRF phosphorylation in untreated Tm-E54K mice in comparison with untreated NTG mice ( Figure 4A ). TRV067 also increased SERCA2 protein expression in Tm-E54K and NTG mice in com- parison with untreated groups. Losartan had no effect on SERCA2 expression ( Figure 4A ).
We tested for interactions between proteins altered because of TRV067 treatment by using coimmunoprecipitations. Shown in Figure 4B , β-arrestin, ERK2, and RSK all coimmunoprecipitated, suggesting a signaling complex of these 3 proteins. β-Arrestin, RSK3, and ERK2 were found in the SRF immunoprecipitation, but SRF was not coimmunoprecipitated in the reverse immunoprecipitation, perhaps suggesting a weak or localization-specific interaction with these proteins. We were unable to perform reliable immunoprecipitations of MYPT1/2, likely because of its strong interaction with insoluble proteins. 23 Signaling Activated by TRV067 is ERK1/2 and RSK Dependent To confirm our hypothesized signaling pathway, we used neonatal rat ventricular myocytes (NRVMs) treated with either TRV067 or losartan in the presence of FR180204, an ERK1/2 inhibitor, or BI-D1870, a pan-RSK inhibitor. Losartan had no effect; however, NRVMs treated with TRV067 had increased RSK3, MYPT1/2, and SRF phosphorylation as seen in the chronically treated adult mice. Pretreatment of NRVMs with either FR180204 or BI-D1870 abolished increases in the phosphorylation of these proteins with drug treatment. These data indicate that both ERK1/2 and RSK are activated downstream of β-arrestin-mediated signaling and are required for the increases in downstream phosphorylation (online-only Data Supplement Figure VIA through VIC).
Myofilament Proteins Are Substrates for RSK3 Phosphorylation
In light of results presented above, we hypothesized that RSK3 may be the most proximal kinase able to mediate the effects seen in our mice treated with TRV067. To test this hypothesis, we isolated dephosphorylated myofibrils from Langendorff-perfused mouse hearts and incubated them with recombinant, active RSK3. We found that RSK3 was able to phosphorylate not only MLC2v, but also cTnI and cMyBP-C, but not troponin T or Tm ( Figure 5A through 5C) . To understand what specific residues were being phosphorylated by RSK3 we used phospho-specific antibodies to cMyBP-C and cTnI. RSK3 solely phosphorylated cMyBP-C at the S302 site. We did not see an increase in cMyBP-C phosphorylation at S302 in vivo as we did in these in vitro experiments. We found that RSK3 did not phosphorylate cTnI at S23/24, consistent with our findings that this increase was not attributable to β-arrestin signaling ( Figure 5D ). These results are consistent with our findings that MLC2v phosphorylation was increased in TRV067-treated mice.
β-Arrestins Localize to the M Line and A Band
We hypothesized that β-arrestins may directly scaffold signaling proteins to the myofilaments and that this localization may be related to agonism of the AT1R. To answer this question, we cultured NRVMs and, following treatment, subjected them to a subcellular fractionation protocol to remove the cytosolic, membrane, and nuclear components of the cell, leaving the sarcomeric fraction for analysis. 24 Shown in Figure 6A , cytosolic, membrane, nuclear, and sarcomeric markers are found only within their respective fractions. Western blot analysis of sarcomeric fractions from NRVMs treated for 1 hour with ang II, TRV067, or losartan revealed a significant increase in β-arrestin localization to the sarcomere with TRV067 treatment (Figure 6B ).
NRVMs depleted of their cytosolic and membrane compartments were stained for MF-20, an antibody that recognizes light meromyosin (red) and β-arrestin (green). Under untreated conditions, there was localization of β-arrestin at the M line and the A band, indicated by the yellow striations and diffuse staining surrounding them. When stimulated with TRV067, we found that there was an increase in this localization, which was seen to a lesser extent in ang II-treated cells, and not at all in the losartan-treated cells ( Figure 6C ). Taken together, these results indicate that agonism of the AT1R by biased ligands induced a rearrangement of β-arrestins to a more sarcomeric distribution at the M line and A band.
DISCUSSION
A major new finding reported here is the demonstration that, unlike the ARB, losartan, TRV067, a β-arrestin 2-biased ligand, is able to improve functional and morphological outcomes in a model of familial DCM. Our data indicate that increased MLC2v phosphorylation induced by TRV067 is likely to be the mechanism for the improved systolic function induced by the β-arrestin pathway. We propose that β-arrestin signaling activates a novel ERK1/2-RSK3-mediated phosphorylation of MLC2v, and an increase in MYPT 1/2 phosphorylation, as well. Losartan and TRV067 share the effect of inhibition of Gα q -mediated maladaptive responses in the progression of DCM. However, TRV067 not only reduced maladaptive protein expression, but also improved left ventricular structure and function. In addition, a unique and novel finding is our demonstration that these effects may be mediated, in part, by β-arrestin localization to the sarcomere.
Our results support the hypothesis for a significant role of increased MLC2v phosphorylation in the mechanism by which a β-arrestin 2-biased ligand compensates for the depression in maximum sarcomeric tension and response to Ca 2+ , commonly attributed as a causative factor in the development and progression of DCM. 25, 26 Previous work has indicated that increases in phosphorylation of MLC2v may result in modest increases in Ca 2+ sensitivity, which may be more pronounced in various models of cardiomyopathy, as seen in the TRV067-treated Tm-E54K mice. 27, 28 We also found that the increases in MLC2v phosphorylation restored maximum tension generation to that of untreated NTG fibers in TRV067-treated mice. It is expected that these changes in phosphorylation induced by TRV067, but not losartan, manifest as an improvement in systolic functional parameters. These increases in cardiac function were seen in the absence of an increase in heart rate. A decrease in afterload is known to increase cardiac output, as may be induced by vasodilating agents, such as losartan. Unloading may be necessary for the improvement in cardiac output seen in the Tm-E54K mice treated with TRV067; however, the fact that losartan-treated Tm-E54K mice did not have improved cardiac output suggests that it is not sufficient, at least in our model. This strongly suggests that modification of the myofilaments may be the source of the improved cardiac output in Tm-E54K mice. It is interesting to note that in losartan-treated NTG mice, MLC2v phosphorylation was decreased, along with Ca 2+ sensitivity and maximum tension generation. Although increases in MLC2v phosphorylation can explain the increases in Ca 2+ sensitivity and maximal tension found in TRV067-treated Tm-E54K mice, it is possible that MLC2v phosphorylation is not the sole mechanism for this observation. This is underscored by our finding that there was a significant increase in phosphorylation at cTnI S23/24 in both TRV067-and losartan-treated transgenic mice despite no changes in overall phosphorylation. This suggests that there is a change in the phosphorylation pattern of the phosphorylatable sites of cTnI that may affect the impact of S23/24 phosphorylation. 29, 30 Despite the fact that the S23/24 phosphorylation site is associated with a decrease in myofilament-Ca 2+ sensitivity and no effect on maximum tension generation, no desensitization was Figure 5 . MLC2v, cTnI, and cMyBP-C are substrates for RSK3 in vitro.
Representative Pro-Q diamond stained SDS-PAGE gel (A) and Coomassie R-250 stained SDS-PAGE gel showing an increase in MLC2v, cTnI, and cMyBPC by RSK3 (B). C, Summarized quantification of SDS-PAGE gels. D, Western blot images showing phosphorylation of cMyBP-C at S302 by RSK3 but not S273 or S282 nor cTnI S23/24. Data were analyzed by repeated-measures 2-way ANOVA followed by the Bonferroni post hoc test for multiple comparisons and represented as means±SEM. n = 4 hearts. * P≤0.05. ANOVA indicates analysis of variance; cTnI, cardiac troponin I; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; SEM, standard error of the mean; Tm, α-tropomyosin; and TnT, troponin T. A, Representative Western blots showing efficiency of subcellular fractionation in neonatal rat ventricular myocytes (NRVMs). B, Representative Western blot and summarized quantification of sarcomeric fractions of NRVMs that were treated for 1 hour with either angiotensin II (ang II), TRV067, or losartan and probed for β-arrestin and α-actinin. There is a basal amount of β-arrestin localized to the sarcomere under basal conditions, whereas analysis revealed that there was a significant increase β-arrestin localized to the sarcomere with TRV067 treatment. C, Images of NRVMs stripped of their cytosolic and membrane components were stained for MF-20, light meromyosin (red), or β-arrestin (green). Colocalization (yellow) which was increased by ang II and TRV067 treatment was observed for β-arrestin at the M line and A band. No increase was seen in the losartan-treated cells. Data were analyzed by 1-way ANOVA followed by a Tukey post hoc test for multiple comparisons and represented as means±SEM. n = 4 separate cultures. *P≤0.05. ANOVA indicates analysis of variance; and SEM, standard error of the mean. observed and maximal tension was increased. 31, 32 The missense mutation in our model has been shown to induce an uncoupling of the S23/24 phosphorylation to myofilament-Ca 2+ sensitivity. 33, 34 This finding, which has been demonstrated only in thin-filament mutations linked to DCM, could explain the lack of response to S23/24 phosphorylation. Studies in human tissue from heart failure and idiopathic DCM have shown that cTnI phosphorylation may be dominant over MLC2v phosphorylation. 32, 35, 36 Taken together, we think this requires that further studies be done to determine the effect of β-arrestin 2-biased agonism of the AT1R in other animal models and human DCM, because the response may differ.
Previous work has implicated RSK family members in the phosphorylation of cTnI, and MYPT1 in smooth muscle, as well, but these roles have yet to be determined in vivo. 21, 37 In our current work, we report that β-arrestin signaling increases ERK1/2 phosphorylation, and RSK3 phosphorylation, as well, signaling to MLC2v. The role of the RSK family members in the development and maintenance of cardiac disease is not understood. Studies have shown an increase in RSK phosphorylation in many pathological states of the heart. 38, 39 However, the investigation of specific RSK isoforms in many of these studies is often absent. When a RSK3 knockout mouse was subjected to transaortic constriction, there was a blunting of the increase in cell size induced by the pressure overload. 40 Although the effects of this knockout do not appear to cause cardiac insufficiency, one apparently consistent finding is a left ventricular wall thinning, and an increase in left ventricular internal dimension, as reported in the literature. 40, 41 Although not investigated by the authors, the beneficial effects of RSK3 knockout in these models may be related to a decrease in myofilament-Ca 2+ response, which has been implicated in the reversal of hypertrophic remodeling. 41, 42 We think this indicates that a basal level of activated RSK3 may be important for normal cardiac function and morphology. Experiments performed in a swimming model of exercise-induced hypertrophy, and in vitro studies, as well, where exercise was mimicked by insulin-like growth factor 1 stimulation, have demonstrated a potential role for an increase in RSK phosphorylation as a physiological adaptation. This upregulation of RSK phosphorylation and activity is most likely a result of downstream activation from ERK1/2. 43 Activation of RSK3 in the setting of pathological hypertrophy is most well-known for its effects at the nucleus, where it interacts with muscle A-kinase anchoring protein and is believed to promote gene transcription related to hypertrophy, and its ability, as well, to upregulate Na + -H + exchanger activity in various cardiac disorders and physiological hypertrophy. 44, 45 Previous studies have suggested that nuclear-localized RSK3 is responsible for maladaptation. 40 Maladaptive signaling that has previously been associated with RSK3 may be blunted in the context of β-arrestin signaling, because ERK1/2 activated by biased ligands remains cytosolic and fails to activate nuclear transcription factors. 19 Because RSK3 binds to and has a greater and longer duration of activity when bound to ERK1/2, it is likely that RSK3 acts in a similar manner on biased ligand stimulation. 46 This hypothesis is supported by our novel finding of β-arrestin localization to the sarcomere, which was found under both control and treatment conditions, although to a significantly greater degree with biased ligand treatment, and that a β-arrestin-ERK2-RSK3 complex exists in cardiac tissue. The role of this localization in physiological maintenance of cardiac function is unknown. The localization of these proteins to the sarcomere under control conditions suggests that they may be important in the regulation of sarcomeric contraction. Although, to our knowledge, no endogenous biased ligands have been discovered, previous work has suggested that biased β-arrestin signaling may be involved in the cardiomyocyte response to stretch, suggesting a physiological role for these unique signaling pathways. 47 However, β-arrestin localization, the localization of associated proteins, the subcellular interactomes in which they participate, and the functional consequences of these interactions requires extensive future study.
We show here that RSK3 is involved in the phosphorylation of SRF in the heart, which has also been described previously in other models. 20 An increase in SRF phosphorylation promotes the binding to DNA and the transcription of sarcomeric and other cardiac-specific genes. 22, 48, 49 We attribute our finding of an increase in SERCA2 expression in our model to this effect. Taken together with our finding that MLC2v is a RSK3 substrate, we have demonstrated a direct functional consequence of RSK3 in mediating inotropic effects via β-arrestin.
These collective proinotropic effects of a biased ligand add to the beneficial signaling pathways altered by losartan, where Akt phosphorylation was normalized, and β-catenin phosphorylation was increased. β-Catenin has long been implicated in the development of cardiomyopathy and long-term cardiac dysfunction after ischemiareperfusion injury. 50, 51 The effects of TRV067 treatment decreasing Akt phosphorylation differ from previous reports of membrane strain-induced β-arrestin signaling via the AT1R where Akt phosphorylation was increased. 52 These reports were from acute studies using membrane strain, whereas our work is chronic using a peptide agonist. We think that this indicates the existence of discrete receptor and β-arrestin conformations induced by strain in comparison with the ligand-bound state. This thought is supported by studies that have shown that distinct β-arrestin conformations are induced by various combinations of phosphorylated receptor barcodes. Recent work using nuclear magnetic resonance and x-ray crystallography has provided some structural basis for discrete signaling outcomes induced by various receptor conformations or phosphorylation states.
53-55 The AT1R may not possess these phosphorylation patterns that result in discrete signaling outcomes, but it is likely that cytoplasmic-facing receptor conformations may dictate discrete β-arrestin signaling pathways, although they are not currently understood. 53 We also found that, shared by TRV067 and losartan, phosphorylation of PLN at S16 and cTnI at S23/24 increased in Tm-E54K mice. The increases in PLN phosphorylation were shared in the NTG animals treated with losartan, but not TRV067. These are canonical protein kinase A phosphorylation sites that are phosphorylated in response to β-adrenergic stimulation. Ang II is known to inhibit adenylate cyclase in a Gα i -dependent manner, and ARBs have been shown to prevent this inhibition. [56] [57] [58] Perhaps TRV067 acts similarly to losartan to increase protein kinase A activity in a β-arrestin-independent manner. However, we did not observe an increase in other protein kinase A-phosphorylatable sites, such as cMyBP-C, nor an increase in heart rate in these animals treated with TRV067 or losartan.
Recently, a clinical trial testing the efficacy of using acute treatment with a β-arrestin 2-biased AT1R modulator, TRV027, for acute decompensated heart failure (AHF) failed to meet primary and secondary end points. This trial entitled BLAST-AHF (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure) (NCT01966601) is unique in that it is the first to bring a cardiovascular-targeted biased ligand to any patient population. 59 Although AHF and DCM have a common major symptom of impaired systolic function, AHF generally results from a rapid decompensation from chronic heart failure resulting in pulmonary congestion and severely depressed left ventricular function. 59 There are key differences between BLAST-AHF and our current work. We have tested the effects of TRV067 given by constant treatment over 12 weeks, whereas the effects of TRV027 were tested in the AHF population over a 48-to 96-hour period via intravenous infusion in comparison with placebo. 59 This allowed us to investigate the impact of β-arrestin 2-biased signaling in DCM over time in comparison with losartan. The TRV family AT1R-biased ligands cannot be used to test the effectiveness of this treatment strategy in a chronic, clinical setting, because they are peptide drugs with a very short half-life of between 2 and 13 minutes. 60 Chronic treatment will require the development of drugs with a longer half-life.
In this study, we used different biased ligand compound than in BLAST-AHF. We have noted no differences in signaling indicators to suggest that the effects of TRV067 are different from its sister peptides. This does not exclude the possibility that the downstream signaling mechanisms may have nuanced differences we have yet to appreciate. Figure 7 illustrates our hypothesis for the downstream signaling mechanism activated by biased agonism of the AT1R by TRV067. TRV067 stimulation activates ERK1/2 and subsequently RSK3. RSK3 phosphorylates MLC2v and MYPT1/2 to increase the myofilament-Ca 2+ response and improve cardiac function. RSK3 activated by β-arrestin phosphorylates SRF leading to an increase in SERCA2 expression. A pathway shared by both TRV067 and losartan results in a decrease in Akt and GSK3β phosphorylation, resulting in an increase in β-catenin phosphorylation and a decrease in β-MHC expression, and an increase in phosphorylation of cTnI and PLN. This Figure 7 . Proposed mechanism by which TRV067 improves cardiac function and morphology in DCM.
Boxes in blue indicate pathways altered by both losartan and TRV067, whereas boxes in green indicate pathways only altered by TRV067. AT1R indicates angiotensin II receptor; cTnI, cardiac troponin I; DCM, dilated cardiomyopathy; β-MHC, β-myosin heavy chain; and PLN, phospholamban. study provides preclinical, mechanistic evidence that biased ligands may be a viable approach to the treatment of DCM.
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